| CTRI Number |
CTRI/2024/05/068164 [Registered on: 31/05/2024] Trial Registered Prospectively |
| Last Modified On: |
31/05/2024 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Siddha |
| Study Design |
Other |
|
Public Title of Study
|
Clinical evaluation of siddha medicine Vithuvagai chooranam for Aan maladu (Male infertility due to Oligospermia) |
|
Scientific Title of Study
|
Single centric non randomised open clinical trial phase II in “Aan maladuâ€(Male infertility due to Oligospermia) with Siddha medicine “Vithuvagai chooranam†among the patients attending OPD at Government siddha medical college hospital, Chennai |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Vignesh S |
| Designation |
PG Scholar |
| Affiliation |
Government Siddha medical college Arumbakkam |
| Address |
Post graduate Department of Pothu maruthuvam, Government siddha medical college, Arumbakkam, chennai
Chennai TAMIL NADU 600106 India |
| Phone |
9095699009 |
| Fax |
|
| Email |
text2vickyy@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Anbu N |
| Designation |
HOD and Professor |
| Affiliation |
Government siddha medical college arumbakkam |
| Address |
Post graduate department of Pothu maruthuvam, Government. Siddha medical college, Arumbakkam, Chennai
Chennai TAMIL NADU 600106 India |
| Phone |
9443279412 |
| Fax |
|
| Email |
nanbu.sumi@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Anbu N |
| Designation |
HOD and Professor |
| Affiliation |
Government siddha medical college arumbakkam |
| Address |
Post graduate department of Pothu maruthuvam, Government. Siddha medical college, Arumbakkam, Chennai
Chennai TAMIL NADU 600106 India |
| Phone |
9443279412 |
| Fax |
|
| Email |
nanbu.sumi@gmail.com |
|
|
Source of Monetary or Material Support
|
| Government siddha medical college Arumbakkam, chennai 600106 Tamilnadu India |
|
|
Primary Sponsor
|
| Name |
Vignesh S |
| Address |
Post graduate department of pothu maruthuvam, Government siddha medical college, Arumbakkam, Chennai 600106 Tamilnadu India |
| Type of Sponsor |
Other [Other(self)] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Vignesh S |
Government siddha medical college Arumbakkam |
Room no S1, Department of PG Pothu maruthuvam, Government siddha medical college Hospital,Arumbakkam, chennai 600106 Tamilnadu India Chennai TAMIL NADU |
9095699009
text2vickyy@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, Government siddha medical college, Chennai |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: N461||Oligospermia, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
NIL |
NIL |
| Intervention |
Vithuvagai Chooranam |
This Siddha Drug will be given as Oral route 1gm bd dose with milk for 48 days for the management of Aan maladu |
|
|
Inclusion Criteria
|
| Age From |
21.00 Year(s) |
| Age To |
50.00 Year(s) |
| Gender |
Male |
| Details |
Male infertile
Oligospermia
Oligoasthenozoospermia
Patient willing to give specimen of semen, blood for investigation
Patient willing to give consent for the study |
|
| ExclusionCriteria |
| Details |
Azoospermia
Teratospermia
Hydrocele
Varicocele
Diabetes mellitus
Klinefelter syndrome
Congenital disorders |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
1)Increased sperm count.
Severe Oligospermia to Moderate Oligospermia
Mild Oligospermia or Normal Moderate Oligospermia to Mild Oligopermia or Normal.
Mild Oligospermia to Normal
2)Improved motility function.
Immotile to Non progressive motility or Progressive motility.
Non progressive motility to Progressive motility. |
12 months |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Improvement in General wellbeing |
12 months |
|
|
Target Sample Size
|
Total Sample Size="40" Sample Size from India="40"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2 |
|
Date of First Enrollment (India)
|
09/09/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
- What additional supporting information will be shared?
Response - Statistical Analysis Plan Response - Clinical Study Report
- Who will be able to view these files?
Response - Anyone
- For what types of analyses will this data be available?
Response - To achieve aims in the approved proposal.
- By what mechanism will data be made available?
Response (Others) - NIL
- For how long will this data be available start date provided 05-06-2025 and end date provided 31-12-2026?
Response - Immediately following publication. No end date.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
|
Brief Summary
|
Infertility is one of the medical conditions that affect millions of people worldwide. It is also a global problem in the field of reproductive health and is one of the major contributors for the decline in birth rate. Infertility is a clinical condition defined by the failure to achieve a clinical pregnancy in 12 or more months of regular unprotected sexual intercourse. In male reproductive system, infertility is most commonly caused by the problems in ejaculation of semen, absence or low level of sperm or abnormal shape(Morphology) and movement(Motility) of the sperm. According to the statistics collected from the World Health Organization (WHO), it is estimated that around 60 to 80 million couples worldwide currently suffer from infertility. Many couples assume that infertility is a female problem and is called a social stigma, but in the general it is only 15% to 20%, but the male is responsible for 20 to 40%.In a World Health Organization multicenter study, 45% of infertile men were found to have either Oligo-zoospermia or Azoospermia. According to WHO’s 2010 guidelines, the qualities of Semen required for fertility are:(1) Volume of Semen per ejaculation must be at least 1.5 ml (2) Sperm count must be at least 15 million /ml (3) Number of Sperm in each ejaculation must be at least 39 million (4) 58% of Sperm per ejaculation must be alive (5) 40% of sperm must be Motile (6) 30% of Sperm must have normal shape and structure. Oligospermia is decrease in the sperm concentration in semen below 15 million sperm per milliliter (WHO, 2010). In Siddha system of Medicine, there are unique combination of medicines which have a solution for MALE INFERTILTY. One such combination is VITHUVAGAI CHOORANAM which is a classical Siddha Herbal formulation mentioned in NOIGALUKKU SIDDHA PARIGAARAM, PAGE NO 300, for the treatment of Aan Maladu (Male Infertility). The therapeutic efficacy of this Siddha formulation is so far not evaluated scientifically, so the author tries to evaluate its efficacy in an open clinical trial. |